Halozyme Therapeutics, Inc. HALO

Halozyme Therapeutics, Inc. es una empresa de tecnología biotecnológica. La empresa otorga licencias de su tecnología a empresas biofarmacéuticas para desarrollar de manera colaborativa productos que combinen su tecnología de entrega de medicamentos ENHANZE con los compuestos de los colaboradores. La enzima principal de la empresa, rHuPH20, se utiliza para facilitar la administración de medicamentos inyectados y fluidos. El producto aprobado de la empresa y los productos aprobados y candidatos a productos de sus colaboradores se basan en rHuPH20, una enzima de hialuronidasa humana recombinante patentada. El producto principal de la empresa, Hylenex recombinante, es una formulación de rHuPH20 que facilita la administración de fluidos subcutáneos para lograr la hidratación, aumentar la dispersión y absorción de otros medicamentos inyectados y, en urografía subcutánea, mejorar la absorción de agentes radiopacos. El rHuPH20 se puede aplicar como una plataforma de entrega de medicamentos para aumentar la dispersión y absorción de otros medicamentos inyectados y fluidos, potencialmente reduciendo la carga de tratamiento.

• Zacks Investment Research 23 sept

  If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now

  A $1,000 investment in Halozyme Therapeutics made in September 2016 would be worth $9,284.68 as of September 23, 2026, representing an 828.47% gain. The biopharmaceutical company's growth is driven by royalties from its ENHANZE drug delivery technology licensed to major pharma partners. However, biosimilar competition for blockbuster drugs and dependence on partner revenues remain concerns.

  

• Zacks Investment Research 23 sept

  Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?

  Halozyme Therapeutics shares rose 3.3% to $115.13 on strong volume, driven by investor optimism around its ENHANZE drug-delivery technology collaborations with major pharmaceutical companies. The company is expected to report quarterly earnings of $2.25 per share (+30.8% YoY) and revenues of $470.95 million (+32.9% YoY). With a 2.6% upward revision in consensus EPS estimates over the past 30 days and a Zacks Rank #2 (Buy) rating, analysts suggest monitoring the stock for potential continued strength.

  

• Zacks Investment Research 21 sept

  Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate

  Biotech companies are increasingly directing capital toward oncology therapeutics, with over $3.9 billion of venture capital flowing into cancer and immunology drug developers in H1 2026. The global oncology drugs market is projected to grow from $256.5 billion in 2025 to nearly $700 billion by 2034, prompting investors to consider biotech ETFs for diversified exposure to this growth opportunity rather than individual stocks.

  

• GlobeNewswire Inc. 10 sept

  Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026

  Acumen Pharmaceuticals announced a virtual Investor Day scheduled for September 16, 2026, to discuss its clinical-stage pipeline. The company is advancing sabirnetug (ACU193), a monoclonal antibody targeting toxic amyloid beta oligomers for Alzheimer's disease treatment, with Phase 2 ALTITUDE-AD trial results expected in late 2026. Acumen is also exploring subcutaneous formulations and collaborating with JCR Pharmaceuticals on enhanced brain delivery technologies.

  

• Zacks Investment Research 8 sept

  Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now?

  Invesco S&P MidCap 400 Pure Growth ETF (RFG) is reviewed as a smart beta ETF offering mid-cap growth exposure with a 0.35% expense ratio. The fund has delivered 16.08% year-to-date returns and 18.85% over the past year, with 102 holdings primarily concentrated in Industrials (27.7%), Healthcare, and Information Technology sectors. It carries medium risk with a beta of 1.12, though cheaper alternatives like Vanguard Morningstar Mid-Cap Growth ETF (VOT) and iShares Russell Mid-Cap Growth ETF (IWP) are available.